Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTRicardo PillaiSun, June 7, 2026 at 7:18 PM GMT+2 3 min readIs KRYS a good stock to buy? We came across a bullish thesis on Krystal Biotech, Inc. on Investment Management Academy’s Substack. In this article, we will summarize the bulls’ thesis on KRYS. Krystal Biotech, Inc.'s share was trading at $310.30 as of May 28th. KRYS’s trailing and forward P/E were 41.55 and 45.45 respectively according to Yahoo Finance.Why OraSure Technologies (OSUR) Is Back in the Spotlight as Sale Pressure BuildsLikoper/Shutterstock.comKrystal Biotech (KRYS) is a gene therapy company focused on rare diseases built around its proprietary HSV-1 vector platform, positioning it as a potential multi-product leader rather than a single-asset biotech. Its commercialized therapy VYJUVEK for DEB already generates high-margin, recurring revenue per patient in a highly underserved ultra-rare population, with significant room for expansion as global patient identification and international reimbursement broaden access.Read More: 15 AI Stocks That Are Quietly Making Investors RichRead More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside PotentialThe investment thesis argues that the market is materially underappreciating both the continued growth runway of VYJUVEK and the optionality embedded in a seven-indication pipeline spanning dermatology, ophthalmology, respiratory, and oncology, where consensus assigns overly conservative success probabilities despite platform consistency. The core differentiator is the HSV-1 vector, which enables non-integrating gene delivery, repeat dosing, and high payload capacity, supporting durable commercial economics and replicable margins across future programs.Key catalysts include European pricing resolution in Q3 2026, Italy’s clean launch in 2H 2026, KB801 and KB803 eye data by end-2026, KB407 cystic fibrosis Phase 3 enrollment in 1H 2026, and Q1 2026 earnings revealing accelerating international traction. The valuation framework highlights a base case upside of 52% to $407 per share driven by steady VYJUVEK scaling and initial pipeline validation, and a bull case of 96% upside to $523 per share driven by faster-than-expected pipeline commercialization and platform re-rating.The bear case centers on clinical failure or stalled pipeline progression, limiting KRYS to a single-asset valuation. Overall, KRYS presents an asymmetric setup where rare disease monopolistic pricing power, underpenetrated patient pools, and expanding pipeline optionality collectively create a high-conviction long-term platform opportunity with meaningful upside if execution across its gene therapy pipeline continues to compound.Terms and Privacy PolicyPrivacy & Cookie SettingsMore Info